Tests BMS-986507 combinations in adults with advanced lung or breast cancer
Tests BMS-986507 with other drugs in adults with advanced cancer.
Plain-language title generated from the registry record
Registry title: A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
Key facts
- Where
- Aviano, Candiolo, Florence, Milan, and Roma, ItalySee the 5 sites
- Phase
- Phase 1/2
Where in Italy
- Cro-IrccsAviano, ItalyTaking people
- Istituto di Candiolo IRCCS - Fondazione del Piemonte per l'OncologiaCandiolo, ItalyTaking people
- Azienda Ospedaliera Universitaria CareggiFlorence, ItalyTaking people
- Fondazione IRCCS - Istituto Nazionale dei TumoriMilan, ItalyTaking people
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro CuoreRoma, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Bristol-Myers Squibb
- Trial code
- NCT06618287
- Record updated
- 23 September 2026
- Original description
The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary efficacy of BMS-986507 combinations in adult participants with advanced solid tumors.Read full original descriptionShow less
A Phase 1/2a, Open-label, Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BMS-986507 (BL-B01D1) Combinations in Adult Participants With Advanced Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary efficacy of BMS-986507 combinations in adult participants with advanced solid tumors.
Inclusion: Participants must have at least one measurable lesion per response evaluation criteria in solid tumors; Participants must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1; Participants must have a life expectancy of at least 3 months at the time of the first dose; Group A: Participants must have pathologically confirmed locally advanced or metastatic NSCLC with an EGFR exon 19 deletion or L858R mutation in exon 21, either alone or in combination with other EGFR mutations, which may include T790M in exon 20. Participants with other EGFR mutations (including but not limited to, exon 21 L861Q, exon 18 G719X, and exon 20 S768I mutations, etc.) will also be allowed; Group B: Participants must have pathologically confirmed locally advanced or metastatic NSCLC; Group C: Participants must have pathologically confirmed locally-advanced, recurrent inoperable, or metastatic TNBC or ER-low, HER2-negative BC; Group D: Participants must have pathologically confirmed locally-advanced, recurrent inoperable, or metastatic TNBC per ASCO/CAP criteria, based on the most recently analyzed biopsy or another pathology specimen; Group E: Participants must have pathologically confirmed locally advanced or metastatic NSCLC, not amenable to treatment in curative intent.
Exclusion: Participants must not have any mixed Small Cell Lung Cancer (SCLC) and Non-Small Cell Lung Cancer (NSCLC) histology; Participants must not have a history of serious recurrent infections; Participants must not have a history of severe heart disease; Participants with known mutations in EGFR will be excluded (Group A,B and E); Other protocol-defined Inclusion/Exclusion criteria apply.